BOSTON — The CEO of the drugmaker GSK on Wednesday said the company has had a minimal role in the Food and Drug Administration’s effort to update the prescribing information of a long-shelved drug so that it can be used to treat a condition often associated with autism.
The FDA’s request that the company update the prescribing information for its decades-old therapy leucovorin is “an administrative request,” the CEO, Emma Walmsley, said during a panel discussion at the STAT Summit.
“We have no commercial interest, we have no scientific research, and we’re not pursuing it,” she added. “So it’s just the administration at this stage.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
